Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome

References

• Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis 2001; 32: 186–190
   PubMedGoogle Scholar
• Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071–1079
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Morris AJ, Dobson ME, et al. Candida lusitaniae: an important emerging cause of candidemia. Infect Dis Clin Pract 1996; 5: 273–278
   Google Scholar
• Wingard R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115–125
   PubMed Web of Science ®Google Scholar
• Merz WG. Candida lusitaniae: frequency of recovery colonization, infection and amphotericin B resistance. J Clin Microbiol 1984; 20: 1194–1195
   PubMed Web of Science ®Google Scholar
• Holzschu DL, Presley HL, Miranda M, Phaff HJ. Indentification of Candida lusitaniae as opportunistic yeasts in humans. J Clin Microbiol 1979; 10: 202–205
   PubMedGoogle Scholar
• Sanchez V, Vasquez JA, Barth-Jones D, et al. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol 1992; 30: 3005–3008
   PubMedGoogle Scholar
• Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol 1989; 27: 236–240
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359: 1135–1144
   PubMed Web of Science ®Google Scholar
• McClenny NB, Fei H, Baron EJ, et al. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother 2002; 46: 1325–1328
   PubMed Web of Science ®Google Scholar
• Pietrucha-Dilanchian P, Lewis RE, Ahmad H, Lechin AE. Candida lusitaniae catheter-related sepsis. Ann Pharmacother 2001; 35: 1570–1574
   PubMedGoogle Scholar
• Pappagianis HD, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 1979; 16: 123–126
   PubMed Web of Science ®Google Scholar
• Yoon SA, Vasquez JA, Steffan PE, et al. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 1999; 43: 836–845
   PubMed Web of Science ®Google Scholar
• Rex JH, Cooper CR, Jr, Merz WG, et al. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906–909
   PubMed Web of Science ®Google Scholar
• Guinet R, Chanas J, Goullier A, et al. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol 1983; 18: 443–444
   PubMedGoogle Scholar
• Merz WG, Sandford GR. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol 1979; 9: 677–680
   PubMed Web of Science ®Google Scholar
• Sanchez PJ, Cooper BH. Candida lusitaniae: sepsis and meningitis in a neonate. Pediatr Infect Dis J 1987; 6: 758–759
   PubMedGoogle Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 1112: 380–385
   Google Scholar
• Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 1998; 42: 1207–1212
   PubMed Web of Science ®Google Scholar
• Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379–390
   PubMedGoogle Scholar
• Bodey GP. Hematogenous and major organ candidiasis. Candidiasis: Pathogenesis, Diagnosis, and Treatment2d ed, GP Bodey. Raven Press, New York 1993; 279–329
   Google Scholar
• Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122–1128
   PubMed Web of Science ®Google Scholar
• Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 5: 414–421
   Google Scholar
• Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238–245
   PubMed Web of Science ®Google Scholar
• Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520–2522
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Yodoi K, Roling EE, Klepser ME. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 2002; 46: 578–581
   PubMedGoogle Scholar
• Peyron F, Favel A, Michel-Nguyen AM, et al. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol 2001; 39: 339–342
   PubMed Web of Science ®Google Scholar
• Favel A, Peyron F, De Meo M, et al. Amphotericin B susceptibility testing of Candida lusitaniae isolates by flow cytofluorometry: comparison with the Etest and the NCCLS broth macrodilution method. J Antimicrob Chemother 1999; 43: 227–232
   PubMedGoogle Scholar
• Pfaller MA, Messer MA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis 1998; 32: 223–227
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30: 14–80
   PubMed Web of Science ®Google Scholar
• Baker JG, Nadler HL, Forgacs P, Kurtz SR. Candida lusitaniae: a new opportunistic pathogen of the urinary tract. Diagn Microbiol Infect Dis 1984; 2: 145–149
   PubMedGoogle Scholar
• Garcia-Martos P, Diaz J, Castano M, Perez M, Marin P. Peritonitis caused by Candida lusitaniae in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1991; 36: 50
   PubMedGoogle Scholar
• Wendt B, Haglund L, Razavi A, Rath R. Candida lusitaniae: an uncommon cause of prosthetic valve endocarditis (letter). Clin Infect Dis 1998; 26: 769–770
   PubMed Web of Science ®Google Scholar